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Abstract
Replication-defective E1-deleted porcine adenoviruses (PAVs) are attractive vectors for vaccination. As a prerequisite for generating
PAV-3 vectors containing complete deletion of E1, we transfected VIDO R1 cells (fetal porcine retina cells transformed with E1 region of
human adenovirus 5) with a construct containing PAV-3 E1Blarge coding sequences under the control of HCMV promoter. A cell line named
VR1BL could be isolated that expressed E1Blarge of PAV-3 and also complemented PAV214 (E1AE1Bsmall deleted). The VR1BL cells
could be efficiently transfected with DNA and allowed the rescue and propagation of recombinant PAV507 containing a triple stop codon
inserted in the E1Blarge coding sequence. In addition, recombinant PAV227 containing complete deletion of E1 (E1AE1Bsmall  E1Blarge)
could be successfully rescued using VR1BL cell line. Recombinant PAV227 replicated as efficiently as wild-type in VR1BL cells but not
in VIDO R1 cells, suggesting that E1Blarge was essential for replication of PAV-3. Next, we constructed recombinant PAV219 by inserting
green fluorescent (GFP) protein gene flanked by a promoter and a poly(A) in the E1 region of the PAV227 genome. We demonstrated that
PAV219 was able to transduce and direct expression of GFP in some human cell lines.
© 2003 Elsevier Science (USA). All rights reserved.
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Adenovirus (Ad) vectors are frequently used for in vitro
and in vivo gene transfer. They have several features that
make them an attractive tool for gene transfer. Adenoviruses
can be grown to high titers in cultured cells and can trans-
duce both dividing and nondividing cells. To date, the
mostly developed vectors are based on the closely related
human adenovirus serotypes 2 and 5. Since HAV-2 or
HAV-5 have naturally infected more than 50% of the adult
human population (Foy and Grayston, 1976), immune re-
sponses to adenoviruses decrease the efficiency of gene
transfer. Moreover, there are safety concerns regarding
transcomplementation of human Ad vectors by wild-type
human Ad infection (Rademaker et al., 2002). To overcome
some of the problems associated with the use of human
adenoviruses as a vector, we (Reddy et al., 1999a, 1999b;
Zakhartchouk et al., 1998) and others (Klonjkowski et al.,
1997; Michou et al., 1999; Sheppard et al., 1988; Xu et al.,
1997; Tuboly and Nagy, 2001; Farina et al., 2001) are
exploring the utility of nonhuman adenoviruses as expres-
sion vectors for human and animal genes transfer.
Since the E1 region encodes proteins involved in cell
cycle regulation, the deletion of this region reduces the risk
of oncogenic transformation. In addition, deletion of the E1
region reduces the expression of all other early genes to a
larger extent, resulting in lower immune responses to ade-
novirus proteins and thus in long-term expression of a
transgene. Moreover, E1-deleted adenovirus vector pro-
vides a significant safety profile to a vaccine as it reduces
the potential for the spread of the vector to nonvaccinated
contacts or to the general environment. Recombinant human
adenovirus vectors currently used in gene transfer experi-
ments have the E1 region of the viral genome replaced by a
transgene. Since deletion of the E1 region renders the re-
combinant virus replication defective (Stratford-Perricaudet
and Perricaudet, 1991), mutant viruses are grown in a cell
line expressing E1 proteins.
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Among other nonhuman adenovirus species, which are un-
der development as a vector, is porcine adenovirus type 3
(PAV-3). The complete nucleotide sequence and a transcrip-
tional map for the whole genome has been reported (Reddy et
al., 1998). This has facilitated the construction of the full-
length genomic clone of the PAV-3 genome (Reddy et al.,
1999b) and recombinant PAV-3s (Reddy et al., 1999a, 1999b;
Zhou and Tikoo, 2001). Earlier, we reported the characteriza-
tion of E1 proteins and construction of a recombinant PAV214
with a 1060-bp deletion in the E1 region (Zhou and Tikoo,
2001). In this report, we describe the construction of the re-
combinant PAV-3 with the E1 region (2750 bp) completely
deleted. In addition, we constructed E1-deleted recombinant
expressing green fluorescent protein (GFP) that was used to
detect vector capability to infect human cells in vitro.
Results
Generation of E1-complementing cell line
Since the production of E1-deleted adenovirus vectors
relies on transcomplementation of the E1 functions in helper
cells, earlier we developed a cell line (VIDO-R1) by trans-
formation of fetal porcine retina cells with the plasmid DNA
containing the E1 sequence of HAV-5 (Reddy et al., 1999a).
This cell line could complement the E1A and/or E1Bsmall
defect of PAV-3 (Zhou and Tikoo, 2001). However, at-
tempts to rescue the recombinant PAV-3 containing the
insertional inactivation/deletion of E1Blarge proved unsuc-
cessful even on VIDO R1 cells. We hypothesized that the
E1Blarge protein of PAV-3 may be required for rescuing the
E1Blarge-deleted PAV-3.
To develop a cell line expressing PAV-3 E1Blarge pro-
tein, subconfluent monolayers of VIDO R1 cells were trans-
fected with plasmid pIREShyE1BL (Fig. 1A) using lipofec-
tin (Invitrogen). The plasmid pIREShygE1BL contains the
PAV-3 E1Blarge coding sequence under the control of the
constitutive human cytomegalovirus (HCMV) immediate
early (IE) promoter. The plasmid also has a selection
marker, the hygromycin B phosphotransferase gene fused to
the internal ribosome entry site (IRES) sequence of the
encephalomyocarditis virus at the 5 end and bovine growth
hormone (BGH) poly(A) signal at the 3 end. IRES permits
the translation of two open reading frames from one mRNA.
Fig. 1. PAV-3 EIBlarge expressing cell clones. (A) Schematic diagram of the plasmid pIREShyEIBL. (B) Southern blot analysis. Hygromycin-resistant clones
(lanes 1 to 7) obtained after transfection of VIDO R1 cells with pIREShyEIBL were used to prepare genomic DNA for Southern blot analysis using 1.9-kb
HindIII fragment as a probe. Lane P, 1.9-kb Hind III fragment; Lane U, VIDO RI cells transfected with control plasmid. Expected band size is shown on
the right. (C) Analysis of ethidium bromide-stained RT-PCR products. Products of RT-PCR using DNAse-treated RNA isolated from different hygromycin-
resistant clones (lanes 1 to 7) or of PCR using DNA (lane P) as a template were synthesized using primer pair for PAV-3 EIBlarge (described under Materials
and methods). RNA with reverse transcriptase (Y); RNA without reverse transcriptase (N). Size marker (M) DNA and expected band size is shown on the
right. (D) Western blot analysis of EIBlarge protein. Proteins from uninfected VIDO R1 (lane U), PAV-3-infected VIDO R1 (lane V), or different EIBlarge
cell clones (lanes 1 to 7) were separated by SDS–PAGE (10% gel) under reducing conditions and transferred to nitrocellulose. The separated proteins were
probed in Western blots using PAV-3 anti-EIBlarge serum. Size of the expected band is shown on the right.
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Several hygromycin-resistant colonies appeared 20 days
after transfection. Potential clones were expanded and ana-
lyzed for the presence of E1Blarge gene. Total genomic DNA
was extracted from the cells, digested with HindIII, and
analyzed by Southern blot using 32P-labeled DNA of
E1Blarge gene as a probe. As seen in Fig. 1B, an E1Blarge-
specific fragment of expected length (1.9 kb; Fig. 1B, lane
P) was detected in genomes of different clones (Fig. 1B).
No such band could be detected in cells transfected with
control plasmid (Fig. 1B, lane U)
Initially, the expression of E1Blarge in these clones was
analyzed by reverse transcription (RT)-PCR using primers
specific for PAV-3 E1Blarge. Using specific primers, an
E1Blarge-specific RT-PCR product of expected size (Fig.
1C, lane P) was detected in different cell clones (Fig. 1C,
lanes 1Y to 7Y). The RNA samples with “no RT” control
did not show any bands (Fig. 1C, lanes 1N to 7N), indicat-
ing that the 317-bp fragment was amplified from E1Blarge
mRNA and not from the residual DNA. To confirm the
expression of PAV-3 E1Blarge protein, Western blot analysis
was performed. Anti-E1Blarge serum detected a major band
of 53-kDa protein in different cell clones (Fig. 1D, lanes 1
to 7). A similar band could be detected in PAV-3-infected
VIDO R1 cells (Fig. 1D lane V) but not in uninfected
VIDOR1 (Fig. 1D, lane U) cells.
Based on these results, a cell line named VR1BL was
established. To determine if VR1BL cells homogenously
express PAV-3 E1Blarge protein, the VR1BL cell line was
subjected to immunofluorescence analysis, using rabbit an-
tibody against PAV-3 anti-E1Blarge protein (Zhou and
Tikoo, 2001). As seen in Fig. 2, more than 95% of VR1BL
cells showed bright fluorescence in the nucleus of the cells
(panel B). No such fluorescence was detected in VIDO R1
cells (panel A). These results suggest that VR1BL cells
expresses E1Blarge protein which is similar to native
E1Blarge expressed in PAV-3-infected cells.
To determine the stability of E1Blarge expression,
VR1BL cells were cultured 20 times; split one in four, twice
weekly; and tested for the ability to support the replication
of PAV507 (described below). The results suggest that
VR1BL retained the ability to support the replication of
PAV507. To determine whether the VR1BL could support
the plaque formation, cells cultured in 35-mm-diameter
dishes were infected with wild-type (Fig. 3A) or recombi-
nant (Fig. 3B) PAV-3 and incubated in MEM containing 5%
FBS and 0.75% low melting agarose. Clear plaque forma-
tion was evident on day 8 postinfection.
Transfectability of VR1BL cell line
To determine the transfection efficiency, VIDO R1 and
VR1BL cells in 35-mm-diameter dishes were transfected
with 5 g of plasmid pQB125 by using lipofectin (Invitro-
gen). This plasmid contains green fluorescent protein gene
under the control of a human cytomegalovirus immediate
early promoter. At 48h posttransfection, the cells were col-
lected and the percentage of GFP expressing cells were
determined by FACS analysis. Our results suggest that
VR1BL cells (10.5% GFP positive) were transfected as
efficiently as VIDO R1 cells (10% GFP positive).
To test the ability of the cells to take up large DNA,
VIDO R1 and VR1BL cells were transfected with 8 g of
PacI-digested pFPAV300 (35.6 kb) (Reddy et al., 1999b)
DNA using lipofectin (Invitrogen). After 7–9 days of incu-
bation at 37°C, recombinant PAV300 could be isolated
from both cell lines. These observations suggest that
VR1BL is as efficient as VIDO R1 for the generation of
recombinant PAV-3. In addition, VR1BL could also com-
Fig. 2. Immunofluorescence staining. Confluent monolayers of VIDO R1 (A) or VR1BL (B) were fixed and analyzed by indirect immunofluorescence using
PAV-3 anti-E1Blarge serum and FITC-labeled goat anti-rabbit antibodies.
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plement (data not shown) the replication defect
(E3E1AE1Bsmall deletion) of recombinant PAV214
(Zhou and Tikoo, 2001).
Complementation of PAV-3 E1Blarge insertion mutant
Earlier attempts to isolate a mutant PAV-3 containing
insertional inactivation of E1Blarge expression were unsuc-
cessful using VIDO R1 cells (Reddy et al., 1999a). In order
to determine if VR1BL cells could support the replication of
E1Blarge inactivated mutant PAV-3, cells were transfected
with PacI-digested pFPAV507 (Zhou and Tikoo, 2001)
DNA which contains full-length PAV-3 genomic DNA with
a triple phase stop codon inserted in E1Blarge (nt 2109) and
deletion of the E3 region (nt 28,112–28,709). After 14
days of transfection, cells showing cytopathic effects were
freeze–thawed twice and the recombinant virus named
PAV507 was plaque purified and propagated. The viral
DNA was isolated from virus-infected cells by Hirt’s ex-
traction method (Hirt, 1967) and analyzed by agarose gel
electrophoresis after digestion. As pFPAV507 contains an
additional SpeI enzyme site (Fig. 4A), the recombinant viral
DNA was digested with SpeI. As seen in Fig. 4B, the
PAV507 genome contains an extra band of 2190 bp (lane 4)
which is not present in wild-type PAV-3 (lane 1).
Construction of the E1-deletion mutant of PAV-3
Taking advantage of homologous recombination in
Escherichia coli strain BJ5183, we constructed the plasmid
pFPAV227, containing the full-length genome of PAV-3
with the deletion of E1 (nt 524–3274) and a partial deletion
of E3 (nt 28,112–28,709). Transfection of VR1BL cells
with PacI-digested pFPAV227 DNA produced a cytopathic
effect in 14 days. The virus named PAV227 was amplified
in VR1BL cells and the viral DNA was extracted from the
infected cells. The DNA was analyzed after digestion with
restriction enzyme SpeI. The wild-type PAV-3 had SpeI
fragments of 724, 3510, and 29,860 bp (Fig. 4, lane 1). In
contrast, PAV227 had SpeI fragments of 527, 724, 3510,
and 26,000 bp (Fig. 4, lane 2). This is consistent with the
expected SpeI fragments of wild-type and the deletion mu-
tant PAV227 (Fig. 4A).
Construction of E1 deletion based recombinant
To determine if E1-deleted PAV-3 can be used to ex-
press a foreign gene, we constructed a recombinant PAV-3
expressing GFP. Using homologous recombination machin-
ery of E. coli (Chartier et al., 1996), the full-length GFP
gene (flanked by HCMV IE promoter and BGH poly(A)
signal) was inserted into the E1 region of PAV227 genome
in the same orientation as the E1 creating plasmid
pFPAV219. The PacI-digested pFPAV219 DNA trans-
fected into VR1BL cells produced a cytopathic effect in 14
days. The virus named PAV219 was amplified in VR1BL
cells and virion DNA was extracted from infected cells. The
presence of a foreign gene (e.g., GFP) in the viral genome
was confirmed by SpeI restriction enzyme analysis. The
wild-type PAV-3 had SpeI fragments of 724, 3510, and
29,860 bp (Fig. 4, lane 1). In contrast, PAV219 had SpeI
fragments of 547, 724, 828, 849, 3510, and 26,630 bp (Fig.
4, lane 3). This suggested that recombinant PAV219 con-
tains GFP gene in the E1 region of PAV-3. To demonstrate
Fig. 3. Plaque formation. Confluent monolayers of VRIBL were infected with wild-type PAV-3 (panel A) or recombinant PAV227 (B) and incubated under
an agarose overlay. The appearance of plaques was examined using an Axiovert 25 inverted microscope equipped with a digital camera.
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that PAV219 expresses GFP, swine testicular (ST) cells
were infected with an m.o.i. of 1 TCID50/cell or 100
TCID50/cell. At 24 h postinfection, the cells were harvested
and analyzed by flow-activated cell sorting (FACS). As seen
in Fig. 5, the infected cells expressed GFP protein in a
dose-dependent manner (panels B and C). No GFP expres-
sion was detected in mock-infected cells (panel A). This
suggested that recombinant PAV219 expresses GFP pro-
tein.
Growth kinetics of PAV227
To determine the importance of E1Blarge in viral repli-
cation, the growth kinetics of mutant and wild-type PAV-3
were compared in ST, VIDO R1, and VR1BL cells. Mono-
layers of different cells were infected with mutant PAV227
or wild-type PAV-3 and cells were harvested at 12, 24, 36,
48, 60, and 72 h postinfection. Virus from each sample was
released by freeze–thawing and titered on VR1BL cells by
Fig. 4. Restriction enzyme analysis of recombinant PAV-3 genome. (A) Schematic representation of full-length genomes of PAV-3s depicting SpeI restriction
enzyme sites. (B) Viral DNAs were extracted from VR1BL cells infected with wild-type PAV-3 (lane 1), PAV227 (lane 2), PAV219 (lane 3), or PAV507
(lane 4) and digested with SpeI. Sizes of markers (M) are shown in kilobases.
Fig. 5. Quantitation of GFP expression using FACS analysis. VR1BL cells mock infected (A) or infected with an m.o.i. of 1 (panel B) or 100 (panel C) of
recombinant PAV219. At 24 h postinfection, the cells were collected, fixed, and analyzed by flow cytometry.
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DBP detection assay (Zhou et al., 2001). The wild-type
PAV-3 titer was 5  1010 infectious units (IU)/ml at 72 h
postinfection (hpi) on VR1BL cells (Fig. 6B). The titer of
PAV227 was quite similar to that of wild-type PAV-3 virus
(Figs. 6A and B). This suggests that complete deletion of E1
(E1AE1BsmallE1Blarge) in PAV227 did not have any
effect on its ability to propagate in VR1BL cells (E1-
complementing cells). In contrast, we could not observe any
progeny virus in PAV227-infected VIDO R1 cells or ST
cells (Fig. 6B)
Infection of human cell lines with PAV219
To determine if human cell lines could successfully be
transduced with recombinant PAV-3 vector, human cell
lines of different origins were infected with PAV219 at an
m.o.i. of 100 TCID50. At 24 hpi, the cells were harvested
and the percentage of GFP expressing cells was determined
by FACS analysis. As seen in Fig. 7, the transduction
efficiency of PAV219 varied in different human cell lines.
The human embryo kidney (293) cells were transduced as
efficiently as porcine ST cells. However, the transduction
efficiency of PAV219 was 76, 53, 31, 30, and 25% in
SAOS-2 osteosarcoma, HeLa, MRC-5 lung fibroblasts,
U118-MG glioblastoma, and Hep2 carcinoma cells. The
transduction of A549 lung carcinoma, SK-N-MC neuroblas-
toma, and K562 myologenous leukemia cells with PAV219
was negligible.
Discussion
Since adenoviruses are considered one of the most effi-
cient viral vectors for gene delivery (Imler, 1995, Russell,
2000), we (Reddy et al., 1999a, 1999b; Zakhartchouk et al.,
1988; Zhou and Tikoo, 2001) and others (Farina et al., 2001;
Klonjkowski et al., 1997; Michou et al., 1999; Sheppard et
al., 1998; Xu et al., 1997) are developing adenoviruses of
animal origin for use in human gene delivery and vaccina-
tion. In addition, these species-specific adenoviral vectors
are ideal candidates for developing novel recombinant vac-
cines for animals. Earlier, we described the construction,
characterization, and use of E3E1AE1Bsmall-deleted
PAV-3 vector for the expression of foreign genes (Zhou and
Tikoo, 2001). Here, we report (a) the construction of a cell
line expressing PAV-3 E1Blarge protein and (b) the isolation
and use of E3E1AE1BsmallE1Blarge-deleted PAV-3
vector for the expression of a foreign gene.
Earlier, we established the VIDO R1 cell line (fetal
bovine retina cells expressing HAV-5 E1 proteins; Reddy et
al., 1999a) which could support the replication of PAV 214
(E3E1AE1Bsmall deleted; Zhou and Tikoo, 2001). How-
Fig. 6. Virus titer of recombinant and wild-type. (A) Near confluent monolayers of VR1BL, VIDO R1, or ST cells were infected with PAV227. At different
time points postinfection, the cell pellet was freeze–thawed and the virus was titrated on VR1BL cells as described in the text. (B) Production of recombinant
PAV-3 by different cell lines. Near confluent monolayers were infected with wild-type PAV-3 or recombinant PAV227. After 3 days, the cells were collected
and freeze–thawed, and the virus was titrated as described in the text. Titers were expressed as infectious units (IU) in which 1 IU was defined as one positive
focus of DBP stained cells at 3 days postinfection. The dotted line shows the amount of input virus.
Fig. 7. Transduction of human cell lines. Confluent monolayers of different
human cell lines were infected with 100 TCID50 of PAV219. At 24 h
postinfection, cells were collected and GFP expression was monitored by
FACS analysis.
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ever, our repeated attempts to isolate a PAV-3 vector with
either gene deletion or insertional inactivation of E1Blarge
were not successful even in VIDO R1 (E1 complementing)
cells. It is possible that the human E1Blarge protein does not
complement the porcine E1Blarge defect of PAV-3. Since the
E1Blarge gene product of HAV-5 interacts with both host
and viral proteins (White, 1995), the absence of HAV-5
E1Blarge-specific interactions with HAV-5-specific proteins
in VIDO R1 cells may have been responsible for not iso-
lating E1Blarge-defective PAV-3.
To develop a porcine cell line for the generation of
E1Blarge-defective PAV-3, we transfected VIDO R1 cells
with a plasmid pIREShyE1BL containing PAV-3 E1Blarge
coding sequence and hygromycin B phosphotransferase
gene (separated by IRES sequence of EMC [endomyocar-
ditis] virus) under the control of HCMV promoter and BGH
poly(A). This construct is expected to be very effective for
stable transfection because the selective marker and gene of
interest is translated from the same mRNA. A number of
hygromycin-resistant clones were selected. As expected, all
clones contained the integrated E1Blarge sequences of
PAV-3 in their genomic DNA. In addition, all clones were
positive for PAV-3 E1Blarge-specific transcript and expres-
sion of E1Blarge protein. The resulting cell line, named
VR1BL, expresses E1Blarge protein homogenously even af-
ter 20 passages, suggesting that the cell line is stable.
Recombinant PAV227 lacking the E1 (nt 524–3274) and
part of the E3 (nt 28,112–28,709) coding regions grew to
titers similar to those of wild type PAV-3 in VR1BL (E1A
E1Bsmall E1Blarge complementing). In contrast, recombi-
nant PAV227 failed to produce infectious progeny virus in
VIDO R1 (E1AE1Bsmall complementing) or ST cells.
This confirmed our earlier observation (Zhou and Tikoo,
2001) and further suggests that E1Blarge protein is essential
for replication of PAV-3. Similar results have been reported
for E1Blarge of HAV-7 (Abrahamsen et al., 1997). Although
E1Blarge appears to be essential for the efficient replication
of HAV-5 in HeLa cells (Babiss et al., 1985), it appears to
be dispensable for the replication of HAV-5 in A549 and
human embryonic retina cells (Imler et al., 1996) and hu-
man 143 cells (Klessig et al., 1982).
The construction of PAV227 is a step further toward the
development of a PAV-3 vector containing complete dele-
tion of E1 (nt 524–3274) and partial deletion of E3 (nt
28,112–28,709), and therefore should be able to accommo-
date 4.7-kb foreign DNA, an improvement over the capacity
of the currently available PAV-3 vector (Zhou and Tikoo,
2001). The construction of PAV219 further demonstrated
the feasibility of using this vector system for foreign gene
expression. These viruses could be propagated in VR1BL
cells with growth kinetics similar to those of wild type
indicating that neither the extended deletion (complete E1,
E3) nor the foreign gene insertion alters the viability of the
viruses.
Recombinant PAV-3 also has potential as a vector for
gene delivery in humans. In this respect recombinant
PAV219 (expressing GFP) is a valuable tool as it provides
a simple and reliable method for quantitative detection of
transgene expression in different cells. As expected, trans-
duction of different human cell lines with PAV219 was
variable. Interestingly, both human 293 cells and SAOS-2
osteosarcoma cells were transduced efficiently by PAV219.
In addition, human sera containing anti-HAV-5 antibodies
does not neutralize PAV-3 (unpublished observations), sug-
gesting that PAV-3 may be suitable as a gene delivery
vector for the treatment of osteosarcoma in humans.
PAV-3 did not transduce A549 and Hep2 cells as effi-
ciently as does HAV-5 (Horwitz, 1996). Although HAV-5
has been shown to bind to a number of receptor moieties
(Dechecchi et al., 2000; Davison et al., 1999; Hong et al.,
1997), the transduction efficiency of HAV-5 mainly de-
pends on the amount of CAR (Bergelson et al., 1997) and
integrin molecules present on the surface of the cells. In
contrast to HAV, initial interactions between PAV-3 and
host cells is not well understood. No primary receptor for
fiber has been identified and because of the absence of RGD
motif in penton base protein (Reddy et al., 1998), the re-
quirement of cell surface integrins for PAV-3 internaliza-
tion remains to be determined. The fact that PAV-3 trans-
duces A549 and Hep2 cells poorly suggests that PAV-3 may
utilize receptor(s) that is distinct from the CAR receptor.
Similar observations have been reported for ovine adenovi-
rus 287, human adenovirus 3 and CELO virus (Xu and
Both, 1998; Stevenson et al., 1995; Tan et al., 2001).
Materials and methods
Cells and viruses
VIDO R1 (Reddy et al., 1999a) cells were grown and
maintained in minimum essential medium (MEM) supple-
mented with 10% fetal bovine serum (FBS). Swine testic-
ular (ST), 293 (human embryo kidney), MRC-5 (human
lung fibroblasts), A549 (human lung carcinoma), Hep2 (hu-
man larynx carcinoma), HeLa (human cervix carcinoma),
U118-MG (human glioblastoma), SK-N-MC (human neu-
roblastoma), SAOS-2 (human osteosarcoma), and K562
(human myologenous leukemia) cells were cultivated ac-
cording to ATCC recommendations. VR1BL cells were
cultivated and maintained in MEM with 10% FBS and 100
g/ml of hygromycin B. The mutant and wild-type PAV-3
(strain 6618) were propagated and titrated in VR1BL cells
(this study).
Construction of plasmid pIRES hyE1BL
The construction of plasmid pIRES–Hyg will be de-
scribed elsewhere (manuscript in preparation). Briefly, the
hygromycin resistance gene, isolated as a 1.304-kb PCR
fragment using sequence-specific primers and plasmid
pDR2 (Clontech) as a template, was ligated to MscI–
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EcoRV-digested plasmid pCITE-1 (Clontech) to create
plasmid pIRES–Hyg. A 1.6-kb PvuII–EcoRV fragment con-
taining the IRES–Hyg cassette was excised from plasmid
pIRES–Hyg and ligated to EcoRV-digested pCDNA-3 to
create plasmid pcIRES–Hyg. A 1612-bp HindIII fragment
of the PAV-3 genome (nt 1767 to 3379) was blunt-end
repaired with T4 polymerase and ligated to BamHI-digested
(T4 polymerase-treated) plasmid pcIRES–hyg to create
plasmid pIRES hyE1BL.
Recombinant plasmids
The recombinant plasmid vectors were constructed by
standard procedures using restriction enzymes and other
DNA-modifying enzymes.
Construction of pFPAV507
Plasmid pFPAV507 (Fig. 4A) contains full-length
PAV-3 genomic DNA with stop codons in all three reading
frames inserted in E1Blarge (nt 2109) and deletion of the E3
region (nt 28112–28709)(Zhou and Tikoo, 2001).
Construction of pFPAV227
To delete the E1 region, the PAV-3 genome between nt
0 and 524 was amplified by using primers YZ-13 and YZ-14
and pPAVXhoIRL as a template as described previously
(Zhou and Tikoo, 2001). The PAV-3 genomic DNA be-
tween nt 3274 and 4159 was amplified by using primers
P3274 (5-GACTAGTTCCT CT TGCAGGTACGTG-3)
and P6205C (5-TGTCCATCACGGATCCTCAG-3) and
DNA of pPAVXhoIRL as a template. The PCR products
were digested with BamHI and SpeI and gel purified. The
digested products were cloned in pPAVXhoIRL and di-
gested with BamHI in a three-way ligation. The resulting
plasmid, pPAV227XhoIRL carried a 2750-bp (nt 524 to
3274) deletion of E1 and the inserted SpeI site. The plasmid
containing recombinant PAV-3 genome with the deletions
in the E1 and E3 regions (pFPAV227; Fig 4A) was gener-
ated by homologous DNA recombination in E.coli BJ5183
between XhoI-linearized pPAV227XhoIRL and PAV-3 ge-
nome excised by PacI from pPAV-300 (Reddy et al.,
1999b).
Construction of pFPAV219
DNA of pPAV227XhoIRL was digested with SpeI,
blunt-end repaired with T4 polymerase, and ligated to a
2320-bp T4 polymerase-treated BglII–DraIII fragment of
plasmid pQBI25 (QBIOgene), containing the human cyto-
megalovirus immediate-early promoter, gene for GFP, and
bovine growth hormone (BGH) poly(A) signal. The final
plasmid was named pPAV219XhoIRL. The plasmid con-
taining recombinant PAV-3 genome with GFP expression
cassette insertion in the E1 region of E3 and E1 deleted
regions (pFPAV219; Fig. 4A) was generated by homolo-
gous DNA recombination in E.coli BJ5183 between
Eco47III–Tth111I fragment of pPAV227XhoIRL and
PAV-3 genome excised by PacI from pPAV-300 (Reddy et
al., 1999b).
Isolation of recombinant PAV-3
VR1BL cell monolayers seeded in 60-mm dishes were
transfected with 8 g of PacI-digested pFPAV507,
pFPAV219, and pFPAV227 recombinant plasmid DNAs
using the lipofectin method (Invitrogen). After 14 days of
incubation at 37°C, the transfected cells showing cytopathic
effects were collected and freeze–thawed twice, and recom-
binant viruses were plaque purified and expanded on
VR1BL cells.
RT-PCR analysis
For RT-PCR analysis, total RNA was extracted from 106
cells using the TRIzol reagent (Invitrogen). The RNA prep-
arations were treated with 2 U of RNase-free DNase (Am-
bion) at 37°C for 30 min. Then, DNase inactivation reagent
(Ambion) was added. Two micrograms of total RNA was
subjected to analysis using QIAGEN one-step RT-PCR kit
and the specific primers (PBL1, 5-CCCTGCTGGAGGC-
GCGAA-3; PBL2, 5-CACACCT GCTGATAGCTAAC)
for the E1Blarge gene of PAV-3.
Southern blot analysis
Five micrograms of the DNA extracted from the cells
using DNeasy Tissue Kit (QIAGEN) was digested with
HindIII and loaded on 0.8% TAE agarose gel. After elec-
trophoresis, the DNA was transferred to Hybond-N nylon
membrane (Amersham) as described by Sambrook and Rus-
sell (2001). The membranes were then probed by Southern
blot hybridization analysis using random primed
[32P]dCTP-labeled PAV-3 E1Blarge gene as a probe.
Western blot analysis
Five micrograms of cell protein extract was separated on
sodium dodecyl sulfate (SDS)–polyacrilamide gel electro-
phoresis (PAGE) and transferred to nitrocellulose mem-
brane. Nonspecific binding sites on the membrane were
blocked with 1% BSA fraction V. E1Blarge protein of
PAV-3 was detected by exposing the membrane to rabbit
polyclonal anti-sera against E1Blarge of PAV-3 (Zhou and
Tikoo, 2001) followed by anti-rabbit IgG conjugated to
alkaline phosphatase. The blot was developed using AP
conjugate substrate kit (Bio-Rad).
Indirect immunofluorescence microscopy
VIDO-R1 or VR1BL cells were plated on Lab-Tek
chamber slides (Nalge Nunc) and grown to confluency. The
cells were fixed with absolute methanol for 10 min at
20°C. Cells were washed with PBS and incubated with
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rabbit polyclonal anti-E1Blarge serum followed by anti-rab-
bit IgG conjugated to fluorescein isothiocyanate (FITC).
The cells were examined using an Axiovert 200M inverted
microscope (Zeiss) equipped with a cooled CCD camera
and AxioVision 3.0 software.
Virus growth curve
Cells were infected with mutant or wild-type PAV-3 at
an m.o.i. of 5. The infected cells, harvested at the indicated
times postinfection, were lysed in the infection medium by
three rounds of freeze–thawing. Virus titers were deter-
mined by serial dilution infections of VR1BL cells followed
by immunohistochemical detection of DNA binding protein
(Zhou et al., 2001). Titers were expressed as infectious units
(IU) in which 1 IU was defined as one positive focus at 3
days postinfection.
Detection of GFP-positive cells by flow cytometry
The 1  105 cells were infected with PAV219 at the
desired m.o.i. The cells were harvested at 24 hpi, washed in
PBS three times, and analyzed on a FACS Calibur flow
cytometer (Becton Dickinson). Acquired data were ana-
lyzed using Cell Quest software. The efficiency of infection
of human cell lines was calculated as the percentage of
GFP-positive cells in a human cell line divided by the
percentage of GFP-positive cells found after infection of ST
cells.
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